加载中
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
常规交易时段
US$3.075
+US$0.035 · +1.15%
盘中时间采用ET。市场数据可能有所延迟。
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
日内区间
当前US$3.075
52周区间
当前US$3.075
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
强力卖出
估值
2
估值过高
情绪
45
多空交织
风险
82
极高风险
动量
31
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
日内区间
当前US$3.075
52周区间
当前US$3.075
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CHF） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3万 CHF | 40.41万 CHF | 161.3万 CHF | 142.24万 CHF | 291.63万 CHF |
| 毛利 | 3万 CHF | 40.41万 CHF | 161.3万 CHF | 142.24万 CHF | 291.63万 CHF |
| 研究与开发 | 19.02万 CHF | 43.52万 CHF | 94.27万 CHF | 788.35万 CHF | 901.41万 CHF |
| 销售、一般及管理费用 | 188.79万 CHF | 167.52万 CHF | 203.1万 CHF | 326.2万 CHF | 774.63万 CHF |
| 营业费用 | 284.46万 CHF | 315.93万 CHF | 385.59万 CHF | 1196.33万 CHF | 1842.22万 CHF |
| 利息收入 | — | 9165 CHF | 6.4万 CHF | 2.93万 CHF | 5322 CHF |
| 利息支出 | 2421 CHF | 3547 CHF | 2.16万 CHF | 4.89万 CHF | 6.3万 CHF |
| 折旧和摊销 | 8472 CHF | 26.01万 CHF | 30.6万 CHF | 32.31万 CHF | 34.76万 CHF |
| 营业利润 | −281.46万 CHF | −275.52万 CHF | −224.3万 CHF | −1054.09万 CHF | −1550.59万 CHF |
| 净利润 | −672.82万 CHF | 705.58万 CHF | −1055.62万 CHF | −2080.42万 CHF | −1535.19万 CHF |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
